Overview

* DRI Healthcare Q3 total income reaches $48.7 mln, comprehensive loss at $57.7 mln

* Company repurchased 394,000 units for $4.1 mln under NCIB

* DRI Healthcare acquired royalty interest in veligrotug and VRDN-003 for up to $300 mln

Outlook

* Company increased credit facility by $70 mln to support acquisitions

* Company plans to submit Biologics License Application for VRDN-003 by end of 2026

Result Drivers

* INTERNALIZATION - DRI Healthcare completed internalization of investment management, paying a $48 mln termination fee to Persis Capital

* ROYALTY ENTITLEMENT - DRI Healthcare increased its royalty entitlement on Ekterly sales through a one-time payment of $22 mln

* VELIGROTUG & VRDN-003 ACQUISITION - Co acquired royalty interest in veligrotug and VRDN-003, expected to drive future growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Total $48.75

Income mln

Q3 $0.55

Adjusted

Cash

Earnings

per Unit

Q3 Net -$57.86

Income mln

Q3 $36.73

Adjusted mln

EBITDA

Q3 84.00%

Adjusted

EBITDA

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Dri Healthcare Trust is C$19.70, about 20.3% above its November 4 closing price of C$15.70

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)